Measles passed 2,300 cases. Use July to check records (2026)

The short version

CDC counted 2,318 confirmed U.S. measles cases as of July 23. Seven percent of those patients were hospitalized, 93% were unvaccinated or had an unknown vaccination status, and 35 outbreaks had been identified. The immediate household task is simple: find the MMR records before school, camp, travel, or college moves turn a missing record into a last-minute problem. 1

There is no new U.S. vaccine-schedule change in this week's CDC material. Flu is still at a national summer low, but the 2025-26 season's preliminary pediatric death count has reached 188. A new global rubella report shows large gains without eliminating importation risk, and a mouse immunology study does not change any human vaccine decision. 2 3

Measles is the decision that cannot wait for a new policy

The latest CDC page, updated July 24, reports data through July 23: 2,318 confirmed cases, 151 hospitalizations, and no deaths. Children ages 5–19 account for 1,141 cases, or 49% of the total; children younger than 5 account for another 456 cases, or 20%. Most cases are tied to outbreaks: 2,153 cases, or 93%. 1

The vaccination-status split is more useful for a family than the national total. CDC lists 93% of cases as unvaccinated or having an unknown status, 3% as having received one MMR dose, and 4% as having received two doses. An unknown record is not proof that someone is unvaccinated, so check with the clinician, state immunization registry, school, or previous medical office before making assumptions. 1

For children, CDC's current measles-vaccination guidance lists two routine MMR doses: the first at 12–15 months and the second at 4–6 years. Some higher-risk adults need two documented doses at least 28 days apart. Infants 6–11 months old who will travel internationally should receive a travel dose, followed by two doses after the first birthday. 4

MMR is a live vaccine. People who are pregnant, might be pregnant, or have a weakened immune system should talk with a health professional before vaccination; CDC says MMR should not be given during pregnancy. That is a reason to get individualized advice, not a reason to leave a household record unchecked. 4

Flu is quiet now, but August is not the whole season

CDC's Week 28 report covers the week ending July 18 and was posted July 24. Seasonal flu activity remained low. Clinical laboratories found influenza in 126 of 21,736 tested specimens, a 0.6% positivity rate, and outpatient visits meeting the influenza-like-illness definition were 0.9%. The positive specimens were 58.7% influenza A and 41.3% influenza B. 2

One newly reported pediatric flu death brought the preliminary 2025-26 total to 188. That total is not a forecast for the coming season, and CDC can revise it as reports arrive. It is a reminder that a quiet July is a planning window, not evidence that flu vaccination has stopped being useful. 2

CDC's standing flu guidance says everyone 6 months and older should get a seasonal flu vaccine, with rare exceptions. For most people who need one dose, September or October is usually a good target, ideally by the end of October. Children who need two doses should start as soon as vaccine is available because the doses must be separated by at least four weeks. People who cannot return later may reasonably be advised to vaccinate earlier. 5

The current surveillance page also reports no new U.S. human H5 infection this week and no identified person-to-person spread. That is reassuring for the general public, but it does not erase the separate advice for people with direct exposure to poultry, dairy cattle, sick birds, or other animals. 2

What did not change in the vaccine pipeline

CDC's July 21 U.S. Vaccine Names update lists available products, including MMR and seasonal flu vaccines, but it does not announce a new age recommendation or a revised family schedule. The ACIP page still lists the March and June 2026 meetings as canceled because of ongoing litigation, with October 21–23 as the next regular meeting shown. 6 7

MFLUSIVA, Moderna's investigational mRNA flu vaccine, is still a watch item rather than a product to schedule around. The FDA's June 18 page describes an advisory-committee discussion of a requested indication for adults 50 and older and stresses that the committee's recommendations are non-binding. The FDA's current calendar shows that June meeting but no July influenza-vaccine committee action. Moderna's investor page likewise provides links to news and pipeline information but no dated availability notice in the material reviewed for this week's window. 8 9 10

No verified Pfizer influenza-product milestone was reported in the official material available for July 20–27. That leaves the practical choice unchanged: do not postpone a routine fall flu appointment for a future product whose authorization, label, supply, insurance coverage, and price are not yet clear.

A global rubella gain, and one mouse study

A CDC report published July 23 found that 179 of 194 countries had introduced a rubella-containing vaccine into routine immunization by 2024, while 117 had been verified as having eliminated rubella. A modeling analysis estimated that congenital rubella syndrome fell from 101,381 cases in 2012 to 26,859 in 2024. Fifteen countries still had not introduced rubella vaccine, and the report estimated that about 21 million infants lived in those countries in 2024. 3

This is global progress, not a new U.S. schedule. For an American family, its direct relevance is that rubella has not disappeared worldwide, so routine MMR protection still matters before international travel and before pregnancy. The report does not support taking an extra dose outside a clinician's advice.

A Nature Immunology paper published July 21 examined how loss of the Notch2 gene in mice changes dendritic cells, gut bacteria, and autoimmune-like inflammation. The experiments used multiple mouse groups, commonly 3–18 animals per group, and did not test a human vaccine, a vaccine schedule, or a product choice. It is useful background on how tissue and microbial signals shape immunity, not a reason to move a family member's next shot. 11

Five useful actions this week

Check MMR records. Start with anyone who will travel internationally, enter school or camp, move into college housing, or spend time in a crowded group. Resolve missing documentation with a clinician or immunization registry.
Put a fall flu appointment on the calendar. September or October is the usual target for most people who need one dose. Children who need two doses should ask when the first dose can be given.
Do not wait for MFLUSIVA or a new Pfizer milestone. Revisit product choice only when there is an FDA decision and real clinic or pharmacy availability.
Separate ordinary flu planning from H5 exposure advice. If someone has direct contact with potentially infected animals, follow local public-health instructions rather than treating the situation as routine seasonal flu.
For pregnancy or immune-system questions, ask before acting. MMR timing and product choice require individualized medical advice, especially during pregnancy or immune-suppressing treatment.

The CDC's vaccination-trends page does not yet provide a 2026–27 flu-vaccine effectiveness estimate; its respiratory-season data updates ended May 29. Families should therefore use the current Week 28 surveillance report for circulation context, not mistake it for a new-season effectiveness number. 12

Flu is giving families time to plan. Measles is the reason to use that time to verify records now.

This is general information, not individual medical advice. For pregnancy, immune suppression, a previous severe vaccine reaction, or a recent measles exposure, contact a clinician or local health department.

Measles passed 2,300 cases. Use July to check records